Journal
TRENDS IN IMMUNOLOGY
Volume 43, Issue 7, Pages 523-545Publisher
CELL PRESS
DOI: 10.1016/j.it.2022.04.010
Keywords
-
Categories
Funding
- Natural Science Foundation of China [81621004, 92159303, 81720108029, 81930081, 91940305]
- Guangdong Science and Technology Department [2020B1212060018, 2020B1212030004, 2018GZR0201004]
- Bureau of Science and Technology of Guangzhou [20212200003]
- Program for Guangdong Introducing Innovative and Entrepreneurial Teams [2019BT02Y198]
Ask authors/readers for more resources
Immune checkpoint blockade therapies have shown clinical benefit, but many immune-cold solid tumors do not respond. Understanding the mechanisms of cold to hot tumor transition and tumor immunotyping can provide insights for effective therapeutic strategies against cancer.
Immune checkpoint blockade (ICB) therapies have achieved clinical benefit, but most 'immune-cold' solid tumors are not responsive. The diversity of immune evasion mechanisms remains a key obstacle in turning nonresponsive 'cold' tu-mors into responsive 'hot' ones. Therefore, exploring the mechanisms of such transitions and tumor immunotyping can provide significant insights into design-ing effective therapeutic strategies against cancer. Here, we focus on the latest advances regarding local and systemic regulatory mechanisms of immune re-sponses in cold and hot tumors. We also highlight the necessity for tumor immunotyping through the assessment of multiple immunological variables using various diagnostic techniques and biomarkers. Finally, we discuss the challenges and potential clinical applications of immunophenotyping to turn cold tumors hot, which may further guide combined immunotherapies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available